| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,260,000 |
| Market
Cap: |
11.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5036 - $0.5036 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PDS Biotechnology is a clinical-stage immunotherapy company developing a pipeline of molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co. owns the proprietary T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, for treatments in oncology and Infectimune™, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Co. is developing targeted product candidates to treat cancers including Human Papillomavirus associated cancers, melanoma, colorectal, lung, breast and prostate cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barer Sol J |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$495,000 |
I/I |
45,000 |
632,810 |
2.1 |
- |
|
| Barer Sol J |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
587,810 |
587,810 |
|
- |
|
| Loughlin James J |
Director |
– • – |
2015-10-06 |
4 |
A |
$8.60 |
$3,130 |
D/D |
364 |
19,625 |
|
- |
|
| Loughlin James J |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$77,000 |
D/D |
7,000 |
19,261 |
2.39 |
- |
|
| Loughlin James J |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,261 |
12,261 |
|
- |
|
| Marchio Albert N Ii |
Chief Acct. & Op., Asst. Sec. |
• – – |
2015-10-06 |
4 |
A |
$7.24 |
$2,585 |
D/D |
357 |
6,861 |
|
- |
|
| Marchio Albert N Ii |
Chief Acct. & Op., Asst. Sec. |
• – – |
2015-10-06 |
4 |
B |
$11.00 |
$1,100 |
D/D |
100 |
6,504 |
2.66 |
- |
|
| Marchio Albert N Ii |
Chief Acct. & Op., Asst. Sec. |
• – – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,504 |
5,504 |
|
- |
|
| Leuthner Brian A |
Chief Executive Officer |
• • – |
2015-10-06 |
4 |
A |
$8.60 |
$688 |
D/D |
80 |
550,958 |
|
- |
|
| Leuthner Brian A |
Chief Executive Officer |
• • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,672 |
550,878 |
|
- |
|
| Hove Anders D |
Director |
– • – |
2015-10-06 |
4 |
A |
$8.60 |
$401,319 |
I/I |
46,665 |
2,068,582 |
|
- |
|
| Hove Anders D |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$4,950,000 |
I/I |
450,000 |
2,021,917 |
2.1 |
- |
|
| Hove Anders D |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,571,917 |
1,571,917 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2015-10-06 |
4 |
A |
$7.75 |
$12,795 |
I/I |
1,651 |
83,592 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2015-10-06 |
4 |
B |
$11.00 |
$495,000 |
I/I |
45,000 |
81,941 |
1.99 |
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
36,941 |
36,941 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2015-10-06 |
4 |
A |
$6.79 |
$16,140 |
D/D |
2,377 |
41,656 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
39,279 |
39,279 |
|
- |
|
| Vaish Renu |
V.P., Global Reg. Affairs |
• – – |
2015-10-06 |
4 |
B |
$11.00 |
$3,850 |
D/D |
350 |
350 |
2.66 |
- |
|
| Faleck Herbert J |
Chief Medical Officer |
• – – |
2015-10-06 |
4 |
B |
$11.00 |
$5,500 |
D/D |
500 |
500 |
2.74 |
- |
|
| Macdonald R. Loch |
Chief Scientific OfficerOffice |
• • – |
2015-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
548,205 |
|
- |
|
| Leuthner Brian A |
Chief Executive OfficerOfficer |
• – – |
2015-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
548,205 |
|
- |
|
122 Records found
|
|
Page 5 of 5 |
|
|
